| Terminated | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage NCT03138499 | Bristol-Myers Squibb | Phase 3 |
| Completed | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices NCT02856646 | Bristol-Myers Squibb | — |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Unknown | Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation NCT02087657 | University of Kansas Medical Center | N/A |
| Unknown | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Imm NCT02007811 | University of Erlangen-Nürnberg Medical School | Phase 1 / Phase 2 |
| Completed | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Mal NCT01854567 | Mesoblast, Ltd. | Phase 3 |
| Completed | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant NCT01904175 | Duke University | — |
| Completed | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor NCT01696461 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Recruiting | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE NCT01555892 | Baylor College of Medicine | Phase 1 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or NCT01458288 | GPCR Therapeutics, Inc. | Phase 2 |
| Completed | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma NCT01665768 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit NCT01527838 | Fate Therapeutics | Phase 1 |
| Unknown | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease NCT00797472 | American Scitech International | Phase 2 |
| Completed | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases NCT01336712 | Northside Hospital, Inc. | Phase 2 |
| Completed | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation NCT01283776 | University of Cologne | Phase 2 |
| Completed | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies NCT01321346 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Completed | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancie NCT01221857 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow T NCT01188798 | St. Jude Children's Research Hospital | Phase 3 |
| Terminated | MSC and HSC Coinfusion in Mismatched Minitransplants NCT01045382 | University of Liege | Phase 2 |
| Completed | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor NCT01350245 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic NCT01833884 | Centre Henri Becquerel | N/A |
| Completed | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or R NCT00990587 | University Health Network, Toronto | Phase 1 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Unknown | Host Dendritic Cells in Allograft Patients NCT00935597 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Completed | Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A NCT00924131 | National Cancer Institute (NCI) | — |
| Completed | Umbilical Cord Blood Transplant for Hematological Malignancies NCT00891592 | University of Pennsylvania | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function NCT00652626 | Celgene | Phase 1 |
| Completed | Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma NCT00705250 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas NCT00685997 | UMC Utrecht | — |
| Completed | Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies NCT00691210 | Columbia University | Phase 1 |
| Completed | A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological NCT01315132 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Pati NCT00667615 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T NCT00648037 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant NCT00597714 | David Rizzieri, MD | Phase 2 |
| Terminated | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transp NCT00674427 | University of Pennsylvania | Phase 1 |
| Completed | Investigation of the Cylex® ImmuKnow® Assay NCT00569842 | Indiana University School of Medicine | — |
| Completed | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients W NCT00665314 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308 | Indiana University | N/A |
| Completed | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Mye NCT00469729 | Gamida Cell -Teva Joint Venture Ltd. | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma NCT00484874 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematolog NCT00460694 | Singapore General Hospital | Phase 1 / Phase 2 |
| Completed | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma NCT00343564 | Cytokinetics | Phase 1 / Phase 2 |
| Active Not Recruiting | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) NCT00368082 | Baylor College of Medicine | Phase 1 |
| Terminated | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation NCT00698685 | University of Arizona | Phase 2 |
| Completed | Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies NCT00256191 | Cortice Biosciences, Inc. | Phase 1 |
| Completed | A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease NCT00284804 | Bristol-Myers Squibb | Phase 2 |
| Completed | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children NCT00552825 | Sheba Medical Center | — |
| Completed | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants NCT00606437 | Duke University | Phase 1 |
| Completed | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Mal NCT00150462 | Amgen | Phase 1 |
| Completed | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus NCT00133367 | Massachusetts General Hospital | Phase 2 |
| Completed | Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease NCT00385788 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease NCT00165412 | Dana-Farber Cancer Institute | — |
| Withdrawn | Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disea NCT00129753 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Quality of Life Among Survivors of Hodgkin Lymphoma NCT00598728 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies NCT00990717 | University Health Network, Toronto | Phase 1 |
| Completed | Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Di NCT00551798 | University Hospital, Limoges | N/A |
| Completed | Behavioral Intervention For BMT/SCT Survivors NCT00579917 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancie NCT00718757 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Psychosocial Impact of Cancer-Related Female Infertility NCT00386217 | M.D. Anderson Cancer Center | — |
| Completed | AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increas NCT00396201 | Genzyme, a Sanofi Company | Phase 2 |
| Recruiting | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies NCT00131014 | Dana-Farber Cancer Institute | — |
| Completed | Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgki NCT00147875 | University of Cologne | Phase 1 / Phase 2 |
| Active Not Recruiting | Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation NCT00165425 | Dana-Farber Cancer Institute | N/A |
| Completed | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation NCT00144677 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease NCT00209014 | Emory University | Phase 2 |
| Completed | Amifostine for Head and Neck Irradiation in Lymphoma NCT00136474 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy NCT01085058 | WiSP Wissenschaftlicher Service Pharma GmbH | Phase 2 / Phase 3 |
| Completed | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF NCT00952237 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Completed | Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma NCT00232440 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Completed | Efficacy Study of Outpatient Therapy for Lymphoma NCT00163761 | Bayside Health | Phase 2 |
| Completed | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation NCT00144703 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease NCT01702961 | Baylor College of Medicine | N/A |
| Completed | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00683046 | University of Chicago | Phase 2 |
| Completed | Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy NCT00165438 | Dana-Farber Cancer Institute | — |
| Terminated | Stem Cell Transplant for Hematological Malignancy NCT00176930 | Masonic Cancer Center, University of Minnesota | N/A |
| Recruiting | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Trans NCT01890486 | Wake Forest University Health Sciences | — |
| Terminated | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation NCT00038818 | M.D. Anderson Cancer Center | N/A |
| Completed | Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors NCT00165308 | Dana-Farber Cancer Institute | N/A |
| Completed | Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma NCT00163748 | Bayside Health | Phase 2 |
| Completed | Allogeneic Transplantation From Related Haploidentical Donors NCT00185692 | Stanford University | Phase 2 |
| Completed | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies NCT01499147 | University of Illinois at Chicago | N/A |
| Completed | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants NCT00001830 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors NCT00179816 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 / Phase 2 |
| Recruiting | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease NCT00398177 | Stanford University | — |
| Completed | Allogeneic Blood Stem Cell Transplantation NCT00423709 | M.D. Anderson Cancer Center | N/A |
| Completed | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia NCT00001575 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Spectroscopy With Surface Coils and Decoupling NCT00581815 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplem NCT00592111 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers NCT00608452 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas NCT00001430 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodg NCT00587873 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Mantle Irradiation for Hodgkin's Disease NCT00165269 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease NCT00000626 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| No Longer Available | This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Pat NCT00720603 | Genzyme, a Sanofi Company | — |